DynPort secures $32.3 million service contract from the NIAID
This article was originally published in Scrip
DynPort Vaccine has received a contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the US NIH, to establish and operate a Phase I clinical trial unit for infectious disease therapeutics. The contract is valued at approximately $32.3 million over seven years. DynPort will team up with Quintiles Transnationalto complete the project. Under the agreement, DynPort and Quintiles will assess the safety of investigational therapeutic products being studied by NIAID, and determine pharmacokinetic and pharmacodynamic properties of up to four new investigational products per year. DynPort will provide overall project management, clinical operations management, quality assurance and co-development of protocols. Quintiles will provide Phase I clinical research and support services. Work will be performed by DynPort at its headquarters in Maryland.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.